ArticleCureus2025
Downregulation of miRNA-590 and miRNA-182 in Early-Stage Mycosis Fungoides in Skin of Color Patients.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMycosis fungoides (MF), especially in skin of color and early stages, lacks specific and sensitive biomarkers for advanced understanding of its pathogenesis, diagnosis, and prognosis. This study aimed to investigate whether miRNA-590 and miRNA-182 have a role in the pathogenesis of early-stage MF and their potential diagnostic and prognostic values in skin of color patients.
methodsThis single-center prospective cohort study with a two-year follow-up included 30 adult Egyptian patients with early MF (IA-IIA) at the time of diagnosis and 20 healthy controls. Serum levels of both miRNA-590 and miRNA-182 were detected in patients at the time of diagnosis relative to controls. Cutaneous lymphoma international prognostic index and clinical progression risk were also determined. Follow-up was conducted every six months over a two-year period to detect disease progression.
resultsThere was a statistically significant downregulation of both miRNA-590 and miRNA-182 in patients at the time of diagnosis compared to controls (p = 0.01). Additionally, there were statistically insignificant correlations between serum levels of both miRNA-590 and miRNA-182 and the two-year outcome (p = 0.4 and 0.5, respectively).
conclusionThis study highlighted the potential dual role (oncogenes/tumor suppressors) of both miRNA-590 and miRNA-182 in the development of early MF and the lack of their progression prediction values in skin of color patients. However, further larger-scale studies are required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.